Cargando…
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control. There is potentially a large patient population that may also benefit from PARP inhib...
Autores principales: | Ström, Cecilia E., Helleday, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030856/ https://www.ncbi.nlm.nih.gov/pubmed/24970153 http://dx.doi.org/10.3390/biom2040635 |
Ejemplares similares
-
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022) -
Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma
por: Magalhães, Denise, et al.
Publicado: (2022) -
Expression of Poly(Adenosine Diphosphate-Ribose) Polymerase Protein in Breast Cancer
por: Akanksha,, et al.
Publicado: (2022) -
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer
por: Arora, Ena, et al.
Publicado: (2018) -
Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells
por: Sargazi, Saman, et al.
Publicado: (2019)